Unternehmen Vinings Holdings Inc. Other OTC
Aktien
NDYN
US92744A1051
NDYN
Pharmazeutika
Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
David Mehalick
CEO | Chief Executive Officer | 56 | 28.10.22 |
Brian Cogley
DFI | Director of Finance/CFO | 38 | 17.05.23 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 28.10.22 |
Colleen Delaney
CTO | Chief Tech/Sci/R&D Officer | 57 | 30.08.23 |
Christine Sheehy
CMP | Compliance Officer | 57 | 28.10.22 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Director/Board Member | 62 | 28.10.22 | |
Director/Board Member | 55 | 28.10.22 | |
Christine Sheehy
CMP | Compliance Officer | 57 | 28.10.22 |
Gene Salkind
BRD | Director/Board Member | 71 | 28.10.22 |
Chris Calise
BRD | Director/Board Member | 51 | 28.10.22 |
David Mehalick
CEO | Chief Executive Officer | 56 | 28.10.22 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 28.10.22 |
Director/Board Member | 56 | 28.10.22 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 37 118 593 | 25 373 891 ( 68,36 %) | 0 | 68,36 % |
Unternehmenskontakt
Coeptis Therapeutics Holdings, Inc.
105 Bradford Road Suite 420
15090, Wexford
+
http://www.coeptistx.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+38.51% | 727 Mrd. | |
+33.05% | 599 Mrd. | |
-6.23% | 354 Mrd. | |
+18.78% | 328 Mrd. | |
+1.35% | 277 Mrd. | |
+16.00% | 243 Mrd. | |
+8.09% | 205 Mrd. | |
-5.77% | 203 Mrd. | |
+6.19% | 164 Mrd. |